1
|
Chauhan S, Lian E, Habib I, Liu Q, Anders NM, Bugg MM, Federman NC, Reid JM, Stewart CF, Cates T, Michalek JE, Keller C. Entinostat as a combinatorial therapeutic for rhabdomyosarcoma. Sci Rep 2024; 14:18936. [PMID: 39147820 PMCID: PMC11327338 DOI: 10.1038/s41598-024-66545-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Accepted: 07/02/2024] [Indexed: 08/17/2024] Open
Abstract
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. For the alveolar subtype (ARMS), the presence of the PAX3::FOXO1 fusion gene and/or metastases are strong predictors of poor outcome. Metastatic PAX3::FOXO1+ ARMS often responds to chemotherapies initially, only to subsequently relapse and become resistant with most patients failing to survive beyond 8 years post-diagnosis. No curative intent phase II or phase III clinical trial has been available for patients in the past 10 years (ARST0921). Thus, metastatic ARMS represents a significantly unmet clinical need. Chemotherapy resistance in ARMS has previously been attributed to PAX3::FOXO1-mediated cell cycle checkpoint adaptation, which is mediated by an HDAC3-SMARCA4-miR-27a-PAX3::FOXO1 circuit that can be disrupted by HDAC3 inhibition. In this study, we investigated the therapeutic efficacy of combining the epigenetic regulator entinostat, a Class I Histone Deacetylase (HDAC1-3) inhibitor, with RMS-specific chemotherapies in patient derived xenograft (PDX) models of RMS. We identified single agent, additive or synergistic relationships between relapse-specific chemotherapies and clinically relevant drug exposures of entinostat in three PAX3::FOXO1+ ARMS mouse models. This preclinical data provides further rationale for clinical investigation of entinostat, already known to be well tolerated in a pediatric phase I clinical trial (ADVL1513).
Collapse
Affiliation(s)
- Shefali Chauhan
- Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA
| | - Emily Lian
- Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA
| | - Iman Habib
- Champions Oncology, Rockville, MD, 20850, USA
| | - Qianqian Liu
- Department of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, USA
| | - Nicole M Anders
- Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21231, USA
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USA
- Takeda Pharmaceutical Company, San Diego, CA, 92121, USA
| | - Megan M Bugg
- Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA
| | - Noah C Federman
- Jonsson Comprehensive Cancer Center, University of California Los Ángeles, Los Angeles, CA, USA
- Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA, USA
| | - Joel M Reid
- Mayo Clinic Comprehensive Cancer Center, Rochester, MN, 55905, USA
| | - Clinton F Stewart
- Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | | | - Joel E Michalek
- Department of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, USA
| | - Charles Keller
- Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA.
| |
Collapse
|
2
|
Nicholas BA, Purohit R, Woods AD, Kannan K, Srinivasa G, Bridge JA, Kim JA, Keller C. BCR-ABL is enriched in S- and G 2-cell cycle phases. Leuk Res 2023; 126:107036. [PMID: 36764024 DOI: 10.1016/j.leukres.2023.107036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/03/2023] [Accepted: 02/06/2023] [Indexed: 02/11/2023]
Affiliation(s)
- Bradley A Nicholas
- Children's Cancer Therapy Development Institute, Beaverton, OR 97005 USA
| | - Reshma Purohit
- Children's Cancer Therapy Development Institute, Beaverton, OR 97005 USA
| | - Andrew D Woods
- Children's Cancer Therapy Development Institute, Beaverton, OR 97005 USA
| | | | | | | | - Jin-Ah Kim
- Children's Cancer Therapy Development Institute, Beaverton, OR 97005 USA
| | - Charles Keller
- Children's Cancer Therapy Development Institute, Beaverton, OR 97005 USA.
| |
Collapse
|
3
|
Johler SM, Fuchs J, Seitz G, Armeanu-Ebinger S. Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma. Cancer Immunol Immunother 2016; 65:1465-1476. [PMID: 27629595 PMCID: PMC11029580 DOI: 10.1007/s00262-016-1896-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Accepted: 08/26/2016] [Indexed: 12/15/2022]
Abstract
Macrophage migration inhibitory factor (MIF) is known to be involved in oncogenic transformation, tumour progression, and immunosuppression and is overexpressed in many solid tumours, including paediatric rhabdomyosarcoma (RMS). We investigated the function of MIF in RMS during treatment with cytotoxic drugs. RMS cell lines were analysed by flow cytometry, immunofluorescence staining, and ELISA. We demonstrated the overexpression of MIF in RMS cells and the enhanced expression and secretion after treatment with cytotoxic agents. Migration assays of RMS cells revealed that inhibitors of MIF (ISO-1, Ant.III 4-IPP, Ant.V, sulforaphane (SF)) and blocking antibodies caused reduced migration, indicating a role for MIF in metastatic invasion. Additionally, we investigated the function of MIF in immune escape. The development of a population containing immunosuppressive myeloid-derived suppressor cells was promoted by incubation in conditioned medium of RMS cells comprising MIF and was reversed by MIF inhibitors but not by antibodies. Although most inhibitors may restore immune activity, Ant.III and 10 µM SF disturbed T cell proliferation in a CFSE assay, whereas T cell proliferation was not reduced by 3 µM SF, ISO-1 or antibodies. However, the inhibition of MIF by blocking antibodies did not increase the killing activity of allogenic PBMCs co-cultured with RMS cells. Our results reveal that MIF may be involved in an immune escape mechanism and demonstrate the involvement of MIF in immunogenic cell death during treatment with cytotoxic drugs. Targeting MIF may contribute to the restoration of immune sensitivity and the control of migration and metastatic invasion.
Collapse
Affiliation(s)
- Sarah Maria Johler
- Department of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany
| | - Jörg Fuchs
- Department of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany
| | - Guido Seitz
- Department of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany
| | - Sorin Armeanu-Ebinger
- Department of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
| |
Collapse
|